

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2024

Commission File Number: 001-41933

Haoxi Health Technology Limited

Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District  
Beijing, China

+86-10-13311587976

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

---

---

### **Explanatory Note**

Haoxi Health Technology Limited (the “Company”) is filing this current report on Form 6-K to report its financial results for the six months ended December 31, 2023 and to discuss its recent corporate developments.

Attached as the exhibit to this current report on Form 6-K is:

- (1) a press release dated May 31, 2024, titled “Haoxi Health Technology Limited Reports Unaudited Financial Results For The Six Months Ended December 31, 2023” as Exhibit 99.1.

## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this current report with respect to the Company's current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as "believe," "expect," "plan," "strategy," "prospects," "forecast," "estimate," "project," "anticipate," "aim," "intend," "seek," "may," "might," "could" or "should," and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management's assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

## EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press release titled "Haoxi Health Technology Limited Reports Unaudited Financial Results for The Six Months Ended December 31, 2023"</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this current report on Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

**HAOXI HEALTH TECHNOLOGY LIMITED**

Date: May 31, 2024

By: /s/ Zhen Fan

Name: Zhen Fan

Title: Chief Executive Officer

**Haoxi Health Technology Limited Reports Unaudited Financial Results for The Six Months Ended December 31, 2023**

BEIJING, May 31, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its unaudited financial results for the six months ended December 31, 2023.

**Financial Highlights for the Six Months Ended December 31, 2023**

- Total revenue for the six months ended December 31, 2023 was US\$23.50 million, increased by US\$14.34 million, or 157%, from US\$9.16 million for the same period in 2022.
- Gross profit for the six months ended December 31, 2023 was US\$1.20 million, representing an increase of 65% from US\$0.73 million for the same period in 2022.
- Net income for the six months ended December 31, 2023 was US\$0.76 million, increasing by US\$0.31 million, or 70%, from US\$0.45 million for the six months ended December 31, 2022.

Mr. Zhen Fan, Chairman and Chief Executive Officer of the Company, stated that, “We are pleased to record an increase in revenue of 157% to US\$23.50 million and in gross profit of 65% to US\$1.20 million during the first six months ended December 31, 2023. The growth we achieved during this period underscores our commitment to providing innovative and effective online marketing solutions. Looking ahead, we remain committed to leveraging the power of popular media platforms in China to drive success for our advertiser clients and deliver sustainable value to our shareholders. With our experience in the online marketing industry, we believe HAO is prepared to enhance its financial performance in the future.”

**Recent Developments**

On April 28, 2024, the Company, through its wholly owned subsidiary, Beijing Haoxi Digital Technology Co., Ltd. (“Beijing Haoxi”), entered into a Framework Contract for Cooperation on Information Placement on Media Platforms (the “Framework Contract”) with Wuhan Yiya Simei Dental Clinic Co., Ltd. (“Yiya Dental”), a regional dentistry chain in China. This partnership underscores the Company’s goal in delivering internet marketing solutions. Pursuant to the Framework Contract, Beijing Haoxi agreed to provide comprehensive advertising services on popular social media platforms, such as Douyin, Toutiao, and Xigua Video, for Yiya Dental, through various forms of media, including short-video, text, images, flash, as well as mobile app contents.

On April 29, 2024, the Company, through its wholly owned subsidiary, Beijing Haoxi, entered into a Bidding Data Promotion Rebate Agreement (the “Rebate Agreement”) with Jinan Yanling Biotechnology Co., Ltd. and its subsidiaries and affiliated companies (collectively, “Yanling”). Pursuant to the Rebate Agreement, Beijing Haoxi agreed to provide comprehensive advertising and promotion services to Yanling through advertising platforms, such as Jinri Toutiao (Today’s Headlines), Douyin, and Xigua Video.

---

## Results of Operations for the Six Months Ended December 31, 2023

### Revenue

We generate revenue from providing one-stop online marketing solutions, including traffic acquisition from mainstream online media platforms, content production, data analysis and advertising campaign optimization, to advertisers through the operating entity. Net revenue was \$9.16 million and \$23.50 million for the six months ended December 31, 2022 and 2023, respectively. The increase in our revenue is mainly attributable to the increase in the number of clients we served, which increased from 183 for the six months ended December 31, 2022 to 338 in the comparative period ended December 31, 2023, as well as an increase in the average revenue per client from \$50,070 for the six months ended December 31, 2022 to \$69,538 for the six months ended December 31, 2023. The higher average revenue per client in the current year is mainly attributable to higher advertisement expenditure by our health care industry clients.

The average revenue per client under our advertisement pricing model consists of two components: 1) the average per unit-of-service price, which is the average price per click-through that we charge our advertiser customers, and 2) the quantity of services, which is actual number of click-throughs with respect to each advertiser. The following table shows the components that impact our revenue and their correlation.

		Six Months Ended December 31,	
		2022	2023
Revenue per click-through (\$)	a	0.51	0.97
Average number of click-throughs with respect to each advertiser client	b	98,432	71,627
Average revenue per client (\$)	c=a*b	50,070	69,538
Number of clients	d	183	338
Revenue (\$)	e=c*d	9,162,832	23,503,910

The increase in the revenue per click-through was higher in the current period mainly due to the increasing popularity of ByteDance media platforms, which we mainly collaborated with through ByteDance's subsidiary, Ocean Engine. For the six months ended December 31, 2023, a growing number of our advertiser clients have chosen to place ads on ByteDance's media platforms. In addition, the costs we paid to Ocean Engine to acquire user traffic for our clients' ads were increased, leading to an increase in our service charge.

### Cost of revenue

Our cost of revenue consists primarily of the purchase of online traffic from third-party media platforms after deducting rebates, and salaries and benefits for business operation staff. The cost of revenue increased by \$13.87 million or 164%, from \$8.43 million for the six months ended December 31, 2022 to \$22.30 million for the six months ended December 31, 2023. The increase in cost of revenue was basically in line with the increase in revenue.

### Gross profit and gross margin

Our gross profit increased by \$0.47 million, from \$0.73 million for the six months ended December 31, 2022 to \$1.20 million for the six months ended December 31, 2023. Gross profit as a percentage of revenue ("profit margin") was 5.11% for the six months ended December 31, 2023, lower than 7.97% for the six months ended December 31, 2022, mainly due to market competition. The Company needed to provide rebates to some customers, in order to maintain and expand the customer base.

### Selling and marketing expenses

Our selling and marketing expenses primarily consist of payroll costs and office related expenses. Selling and marketing expenses increased by 44% from \$14,312 in the six months ended December 31, 2022 to \$20,564 in the six months ended December 31, 2023. It was mainly due to an increase in bonuses paid to our sales staff, which were calculated based on sales performance.

### *General and administrative expenses*

Our general and administrative expenses mainly consist of salaries and bonuses, as well as administrative related expenses. General and administrative expenses increased by \$132,326, or 66%, from \$199,284 for the six months ended December 31, 2022 to \$331,610 for the six months ended December 31, 2023. The increase was mainly attributable to an increase in salary and bonuses of the management team and professional fees in connection with our IPO.

### *Research and development expenses*

Our R&D expenses mainly consist of salaries and benefits of our R&D staff developing Bidding Compass and our online ads bidding analysis software. R&D expenses increased by \$7,000, or 29%, from \$23,842 for the six months ended December 31, 2022 to \$30,842 for the six months ended December 31, 2023. It was mainly attributable to the increase in salaries of R&D staff.

### *Income taxes*

We had income taxes of \$39,001 and \$40,030 for the six months ended December 31, 2022 and 2023, respectively.

### *Net (loss)/income*

As a result of the foregoing, we had net income of \$0.45 million and \$0.76 million for the six months ended December 31, 2022 and 2023, respectively.

### **About Haoxi Health Technology Limited**

Haoxi Health Technology Limited is an online marketing solution provider headquartered in Beijing, China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. The Company is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: <http://ir.haoximedia.com>.

### **Forward-Looking Statement**

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the U. S. Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at [www.sec.gov](http://www.sec.gov). The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations

WFS Investor Relations Inc.

Janice Wang, Managing Partner

Email: [services@wealthfsllc.com](mailto:services@wealthfsllc.com)

Phone: +86 13811768599

+1 628 283 9214

**HAOXI HEALTH TECHNOLOGY LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

	December 31, 2023 (Unaudited)	June 30, 2023
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 1,112,634	\$ 1,203,203
Trade receivables, net	218,492	7,748
Supplier advances	3,465,160	2,404,680
Prepaid expense, receivables and other assets	609,793	58,474
<b>Total current assets</b>	<b>5,406,079</b>	<b>3,674,105</b>
<b>Non-current assets</b>		
Property and equipment, net	135,033	143,836
Operating right-of-use asset	46,213	89,544
Deferred listing costs	587,471	556,756
<b>Total non-current assets</b>	<b>768,717</b>	<b>790,132</b>
<b>Total Assets</b>	<b>\$ 6,174,796</b>	<b>\$ 4,464,237</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current Liabilities</b>		
Short-term loans	\$ 722,230	\$ 511,409
Accounts payable	1,001,888	27,312
Due to related parties	81,564	20,210
Advances from customers	1,030,329	1,493,947
Taxes payable	982,535	328,093
Accrued expenses and other liabilities	209,486	41,518
Salary and welfare payable	39,520	37,145
Operating right-of-use liabilities-current	46,213	89,544
Long-term payable-current	13,982	27,344
<b>Total current liabilities</b>	<b>4,127,747</b>	<b>2,576,521</b>
<b>Non-current Liabilities</b>		
Long-term payable	71,140	72,104
Long-term borrowing	254,140	249,107
<b>Total non-current liabilities</b>	<b>325,280</b>	<b>321,211</b>
<b>Total Liabilities</b>	<b>4,453,027</b>	<b>2,897,732</b>
<b>Commitments and contingencies</b>		
<b>SHAREHOLDERS' EQUITY:</b>		
Class A Ordinary Shares (Par value US\$0.0001 per share, 150,000,000 shares authorized, and 12,210,000 and 7,730,000 shares issued and outstanding.	1,221	1,221
Class B Ordinary Shares (Par value US\$0.0001 per share, 50,000,000 shares authorized, and 17,270,000 and 17,270,000 shares issued and outstanding.	1,727	1,727
Additional paid-in capital	2,176,796	2,176,796
Retained earnings (Accumulated deficit)	191,738	(568,460)
Accumulated other comprehensive loss	(649,713)	(44,779)
<b>Total shareholders' equity</b>	<b>1,721,769</b>	<b>1,566,505</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 6,174,796</b>	<b>\$ 4,464,237</b>



**HAOXI HEALTH TECHNOLOGY LIMITED**  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME**

	Six Months Ended December 31,	
	2023 (Unaudited)	2022 (Unaudited)
<b>Revenues</b>	\$ 23,503,910	\$ 9,162,832
Cost of revenues	(22,302,522)	(8,432,603)
<b>Gross profit</b>	<b>1,201,388</b>	<b>730,229</b>
<b>Operating expenses:</b>		
Selling	20,564	14,312
General and administrative	331,610	199,284
Research and development	30,842	23,842
Total operating expenses	<b>383,016</b>	<b>237,438</b>
<b>Income from operations</b>	<b>818,372</b>	<b>492,791</b>
<b>Other income (loss):</b>		
Financial expenses	(16,789)	(6,744)
Other income	(1,355)	
Total other income (loss), net	<b>(18,144)</b>	<b>(6,744)</b>
<b>Income before income taxes</b>	<b>800,228</b>	<b>486,047</b>
<b>Income tax expense</b>	<b>(40,030)</b>	<b>(39,001)</b>
<b>Net income</b>	<b>\$ 760,198</b>	<b>\$ 447,046</b>
<b>Comprehensive income</b>		
Net income	\$ 760,198	\$ 447,046
Foreign currency translation gain (loss)	(604,934)	65,529
<b>Total Comprehensive income</b>	<b>\$ 155,264</b>	<b>\$ 512,575</b>
<b>Earnings per ordinary share*</b>		
– Basic and diluted	<b>\$ 0.03</b>	<b>\$ 0.02</b>
<b>Weighted average number of ordinary shares outstanding</b>		
–Basic and diluted	<b>29,480,000</b>	<b>25,373,333</b>